• IDEAYA Biosciences, Inc. was recently added to multiple Russell growth and small-cap benchmarks, including the Russell 3000, 2500, 2000, Small Cap Comp, and 3000E Growth indexes.
• This broad inclusion significantly raises IDEAYA’s profile among institutional investors, especially passive funds that track these benchmark families for portfolio construction.
• Next, we’ll examine how IDEAYA’s broad Russell growth index inclusion shapes its investment narrative and potential appeal to new investors.

This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

What Is IDEAYA Biosciences' Investment Narrative?

To own IDEAYA today, you have to believe in its targeted oncology pipeline eventually converting into meaningful, durable revenue, despite the company remaining unprofitable and funding itself through equity. The big near term catalyst is still the darovasertib plus crizotinib program, with an NDA targeted for the second half of 2026 and review under the FDA’s RTOR framework, alongside early but expanding data across IDE397, IDE892 and IDE161. The fresh Russell growth and small cap index inclusions may support trading liquidity and broaden the shareholder base, yet they do not fundamentally change the core risk that IDEAYA’s valuation rests on successful clinical and regulatory outcomes. If anything, the recent follow on offering and upcoming lock up expiry keep financing and dilution firmly on the radar.

IDEAYA Biosciences' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Three fair value estimates from the Simply Wall St Community span from US$52.79 to a very large US$617.80, underlining how far apart individual views can be. You are seeing that diversity play out against a story where index inclusion, a recent US$300,000,008 capital raise and an unprofitable profile keep execution risk and dilution very real considerations for IDEAYA’s future performance.

Explore 3 other fair value estimates on IDEAYA Biosciences - why the stock might be worth just $52.79!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your IDEAYA Biosciences research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free IDEAYA Biosciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate IDEAYA Biosciences' overall financial health at a glance.

Contemplating Other Strategies?

Our top stock finds are flying under the radar-for now. Get in early:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• The latest GPUs need a type of rare earth metal called Neodymium and there are only 31 companies in the world exploring or producing it. Find the list for free.
• We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.